8-K: Avadel & Jazz Settle Lawsuits, Secure LUMRYZ IP

Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement resolving all litigation and establishing a long-term licensing agreement for LUMRYZ.

Summary

• Avadel CNS Pharmaceuticals, LLC, a subsidiary of Avadel Pharmaceuticals plc, entered into a Settlement and License Agreement with Jazz Pharmaceuticals, Inc. on October 21, 2025, to resolve multiple previously disclosed lawsuits.
• Jazz will make a settlement payment of $90 million to Avadel CNS and waive its right to receive royalties and/or damages on LUMRYZ sales through September 30, 2025.
• Both Avadel CNS and Jazz agreed to dismiss their respective lawsuits with prejudice, contingent upon the settlement payment.
• Jazz granted Avadel CNS a worldwide, non-exclusive, perpetual, irrevocable, non-terminable, royalty-bearing license to any past, present, or future patents that could be asserted against LUMRYZ for any indication.
• Jazz agreed not to challenge the approval or approvability of LUMRYZ for any present or future indications, including idiopathic hypersomnia.
• Avadel CNS will pay Jazz royalties on LUMRYZ net sales: 3.85% for narcolepsy (subject to potential reduction to 3.75%) through February 18, 2036, and 10% for other indications (including idiopathic hypersomnia, subject to potential reduction to 9.5%) starting no earlier than March 1, 2028, until February 18, 2036.
• Avadel CNS granted Jazz a worldwide, non-exclusive, perpetual, irrevocable, royalty-free, fully paid-up covenant not to sue pertaining to Avadel's patents in connection with Jazz's XYWAV and XYREM products.

Sentiment

Score: 9

Explanation: The settlement is highly positive for Avadel, resolving major legal uncertainties, providing a significant cash infusion, and securing a clear path for future market expansion for its key product, LUMRYZ. This significantly de-risks the company's outlook and enhances its commercial prospects.

Positives

• Avadel will receive a $90 million settlement payment from Jazz Pharmaceuticals.
• Jazz waived its right to receive royalties and/or damages on LUMRYZ sales through September 30, 2025.
• All ongoing litigation between Avadel and Jazz has been dismissed with prejudice, removing significant legal uncertainty and associated costs.
• Avadel secured a perpetual, worldwide license from Jazz for any patents that could be asserted against LUMRYZ, ensuring long-term intellectual property clarity.
• Jazz agreed not to challenge the approval or approvability of LUMRYZ for any current or future indications, including idiopathic hypersomnia.
• A defined pathway for LUMRYZ in idiopathic hypersomnia has been established, with market entry possible as early as March 1, 2028, providing future growth opportunities.

Negatives

• Avadel is obligated to pay ongoing royalties to Jazz on net sales of LUMRYZ: 3.85% for narcolepsy and 10% for other indications (including idiopathic hypersomnia).
• Avadel granted Jazz a royalty-free covenant not to sue concerning Avadel's patents related to Jazz's XYWAV and XYREM products.

Risks

• Actual results and business operations may differ materially from forward-looking statements due to significant risks.
• Factors that could cause actual results to differ from expectations include those described in the Risk Factors section of Avadel's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.
• Forward-looking statements are not guarantees of future performance and should not be unduly relied upon.

Future Outlook

The settlement provides Avadel with long-term clarity on its intellectual property position and commercial rights for LUMRYZ. It establishes a defined pathway for LUMRYZ in idiopathic hypersomnia, with a potential market entry date as early as March 1, 2028, positioning Avadel to advance its differentiated sleep medicines portfolio.

Management Comments

• This settlement provides Avadel with long-term clarity on its intellectual property position and commercial rights.
• With a defined pathway for LUMRYZ in idiopathic hypersomnia, including a certain entry date as early as March 1, 2028, we believe Avadel is well-positioned to advance its differentiated sleep medicines portfolio.

Industry Context

This global settlement resolves significant patent litigation in the competitive sleep disorder market, particularly for narcolepsy and related conditions. It provides Avadel with a clearer path for commercializing LUMRYZ and expanding into new indications like idiopathic hypersomnia, where Jazz's Xyrem and Xywav have been dominant. The resolution reduces legal overhang for Avadel, allowing it to focus on market penetration and product development in a key therapeutic area.

Comparison to Industry Standards

• LUMRYZ was granted seven years of Orphan Drug Exclusivity by the FDA due to a finding of clinical superiority over currently available oxybate treatments.
• The FDA specifically noted that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products (such as Jazz's Xyrem and Xywav) by offering a once-nightly dosing regimen that avoids nocturnal arousal for a second dose.

Legal Proceedings

• Resolution of multiple lawsuits captioned Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (C.A. No. 21-691, 21-1138, 21-1594) and Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al (C.A. No. 22-487, 22-941, 25-09, 25-57, 25-221, 25-435) in the United States District Court for the District of Delaware.

Stakeholder Impact

• Shareholders: Significant positive impact due to resolution of major litigation, substantial cash inflow, and clarity on LUMRYZ's intellectual property and future market expansion, reducing investment risk.
• Employees: Increased stability and clarity regarding the company's strategic direction and product future.
• Customers (patients): Continued access to LUMRYZ for narcolepsy and potential future access for idiopathic hypersomnia, with the benefit of a once-nightly dosing regimen.
• Competitors: The settlement clarifies the competitive landscape in the oxybate market, particularly for Jazz Pharmaceuticals, Inc. and other companies developing sleep disorder treatments.

Next Steps

• The full Settlement Agreement will be filed in the Company's next quarterly report on Form 10-Q.

Key Dates

Recommendation

The global settlement with Jazz Pharmaceuticals is a highly favorable outcome for Avadel. It eliminates significant legal and financial overhang from multiple lawsuits, provides a substantial $90 million cash payment, and secures a perpetual, worldwide license for LUMRYZ patents. Crucially, it establishes a clear and defined pathway for LUMRYZ to enter the idiopathic hypersomnia market as early as March 1, 2028, a major growth catalyst. This resolution de-risks the investment thesis, strengthens Avadel's balance sheet, and unlocks significant future revenue potential, making the stock a strong buy for long-term investors.

Keywords

Avadel Pharmaceuticals, Jazz Pharmaceuticals, LUMRYZ, Narcolepsy, Idiopathic Hypersomnia, Settlement Agreement, Patent Litigation, Biopharmaceutical, Sleep Disorders, FDA Approval, Orphan Drug Exclusivity, XYWAV, XYREM